An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Status: Recruiting
Phase:
Diagnosis: Multiple Myeloma
NCT ID: NCT01833039 (View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 13-307

 

The purpose of this study is to provide patients who have relapsed or refractory Mantle Cell Lymphoma (MCL) with early access to an investigational medication called ibrutinib (PCI-32765) and to collect safety information about the drug.

 

Conducting Institutions:
Massachusetts General Hospital

Overall PI:
Jeffery Barnes, MD, Dana Farber Cancer Institute

Site-responsible Investigators:

Contacts:
Massachusetts General Hospital: Cancer Trials Call Center, 877-789-6100

Eligibility Criteria

Inclusion Criteria: - Patients, 18 years of age and older, with Mantle Cell Lymphoma who have progressive disease after prior therapy are eligible. Exclusion Criteria: - Patients eligible for enrollment in any other ongoing clinical study of ibrutinib are not eligible. - Patients previously treated with ibrutinib are not eligible. - Patients enrolled in another interventional clinical study with therapeutic intent are not eligible.
  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms